LUC00261I2 - - Google Patents

Info

Publication number: LUC00261I2
Authority: LU; Luxembourg

Application number

LU00261C

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-02-22

Filing date

2022-05-13

Publication date

2025-04-25

2022-05-13 Application filed by Pfizer filed Critical Pfizer

2025-04-25 Publication of LUC00261I2 publication Critical patent/LUC00261I2/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Oncology (AREA)
Hematology (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
Emergency Medicine (AREA)

LU00261C 2013-02-22 2022-05-13 LUC00261I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361767947P	2013-02-22	2013-02-22
PCT/IB2014/058889 WO2014128591A1 (fr)	2013-02-22	2014-02-11	Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak)

Publications (1)

Publication Number	Publication Date
LUC00261I2 true LUC00261I2 (fr)	2025-04-25

Family

ID=50151346

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU00261C LUC00261I2 (fr)	2013-02-22	2022-05-13

Country Status (47)

Country	Link
US (3)	US9035074B2 (fr)
EP (2)	EP2958921B1 (fr)
JP (2)	JP6145179B2 (fr)
KR (1)	KR101787858B1 (fr)
CN (2)	CN105008362B (fr)
AP (1)	AP2015008664A0 (fr)
AR (1)	AR094857A1 (fr)
AU (1)	AU2014220357B2 (fr)
BR (1)	BR112015019634B1 (fr)
CA (1)	CA2900703C (fr)
CL (1)	CL2015002303A1 (fr)
CR (1)	CR20150395A (fr)
CU (1)	CU24275B1 (fr)
CY (3)	CY1119502T1 (fr)
DK (2)	DK2958921T3 (fr)
DO (1)	DOP2015000206A (fr)
EA (1)	EA027879B1 (fr)
ES (2)	ES2713052T3 (fr)
FR (1)	FR22C1006I2 (fr)
GE (1)	GEP201606600B (fr)
HR (2)	HRP20171599T2 (fr)
HU (3)	HUE037192T2 (fr)
IL (1)	IL240132B (fr)
LT (3)	LT3290421T (fr)
LU (1)	LUC00261I2 (fr)
MA (1)	MA38347A1 (fr)
MD (1)	MD4735C1 (fr)
ME (2)	ME03301B (fr)
MX (1)	MX374338B (fr)
MY (1)	MY177476A (fr)
NL (1)	NL301155I2 (fr)
NO (2)	NO3052752T3 (fr)
NZ (1)	NZ710411A (fr)
PE (1)	PE20151764A1 (fr)
PH (1)	PH12015501779B1 (fr)
PL (2)	PL2958921T3 (fr)
PT (2)	PT3290421T (fr)
RS (2)	RS58245B1 (fr)
SG (1)	SG11201505816UA (fr)
SI (2)	SI2958921T1 (fr)
TN (1)	TN2015000355A1 (fr)
TR (1)	TR201902525T4 (fr)
TW (1)	TWI507408B (fr)
UA (1)	UA111804C2 (fr)
UY (1)	UY35337A (fr)
WO (1)	WO2014128591A1 (fr)
ZA (1)	ZA201505454B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2605652B1 (fr)	2010-08-18	2017-11-08	Samumed, LLC	Dicétones et hydroxydicétones utiles en tant qu'activateurs de la voie de signalisation de la caténine
US10172789B2 (en)	2013-01-24	2019-01-08	Palvella Therapeutics Llc	Compositions for transdermal delivery of mTOR inhibitors
CN105008362B (zh)	2013-02-22	2017-06-06	辉瑞大药厂	作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3‑d]嘧啶衍生物
MA38421A1 (fr)	2013-02-22	2017-03-31	Samumed Llc	Gamma-dicétones en tant qu'activateurs de la voie de signalisation wnt/?-caténine
JP6585158B2 (ja) *	2014-08-12	2019-10-02	ファイザー・インク	ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体
PT3206686T (pt)	2014-08-20	2020-01-06	Samumed Llc	Gama-dicetonas para o tratamento e prevenção de rugas e do envelhecimento da pele
UA118822C2 (uk) *	2015-05-29	2019-03-11	Вуксі Фортуне Фармасьютікал Ко., Лтд	Інгібітор янус-кінази
US12365689B2 (en)	2015-10-16	2025-07-22	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG11201802990RA (en)	2015-10-16	2018-05-30	Abbvie Inc	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US10550126B2 (en)	2015-10-16	2020-02-04	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en)	2015-10-16	2022-06-21	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en)	2015-10-16	2023-10-03	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN106831779B (zh) *	2015-11-28	2019-07-19	南昌弘益药业有限公司	一类jak激酶抑制剂的新化合物
WO2017143014A1 (fr) *	2016-02-16	2017-08-24	Brian Kim	Inhibiteurs de jak et leurs utilisations
CN110520097B (zh)	2017-01-06	2023-10-27	帕尔维拉治疗股份有限公司	Mtor抑制剂的无水组合物及其使用方法
CN108794480A (zh) *	2017-04-28	2018-11-13	天津药物研究院有限公司	吡咯并嘧啶类化合物、其制备方法和用途
SMT202200134T1 (it)	2018-03-08	2022-05-12	Incyte Corp	Composti di amminopirazindiolo come inibitori di pi3k-y
JP2021530463A (ja)	2018-07-02	2021-11-11	パルヴェラセラピューティクス、インク．	ｍＴＯＲ阻害剤の無水組成物および使用方法
US11046658B2 (en)	2018-07-02	2021-06-29	Incyte Corporation	Aminopyrazine derivatives as PI3K-γ inhibitors
ES3045115T3 (en)	2018-07-06	2025-11-27	Pfizer	Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof
CA3118488A1 (fr)	2018-11-05	2020-05-14	Avista Pharma Solutions, Inc.	Composes chimiques
KR102857917B1 (ko) *	2019-01-30	2025-09-10	펠리카메드 바이오테크놀로지 컴퍼니 리미티드	Jak 억제제 및 그 제조 방법
KR20210114470A (ko)	2019-02-15	2021-09-23	화이자 인코포레이티드	결정질 피리미디닐-3,8-다이아자바이사이클로[3.2.1]옥타닐메타논 화합물 및 이의 용도
US12398141B2 (en)	2019-03-14	2025-08-26	Shanghai Synergy Pharmaceutical Sciences Co., Ltd	JAK kinase inhibitor, preparation method for same, and applications thereof in field of medicine
US20220259209A1 (en) *	2019-06-27	2022-08-18	Glenmark Life Sciences Limited	Process for the preparation of abrocitinib
KR20220059519A (ko) *	2019-09-11	2022-05-10	화이자 인코포레이티드	키나제 억제제에 의한 한선염의 치료
WO2021062163A1 (fr)	2019-09-27	2021-04-01	Disc Medicine, Inc.	Procédés de traitement de la myélofibrose et d'affections associées
EP4125900A1 (fr)	2020-04-04	2023-02-08	Pfizer Inc.	Procédés de traitement de la maladie à coronavirus 2019
CN113637018A (zh)	2020-04-27	2021-11-12	苏州晶云药物科技股份有限公司	磺酰胺类化合物的晶型及其制备方法
WO2021231798A1 (fr)	2020-05-13	2021-11-18	Disc Medicine, Inc.	Anticorps anti-hémojuvéline (hjv) pour le traitement de la myélofibrose
CA3184647A1 (fr) *	2020-05-28	2021-12-02	Pfizer Inc.	Derives de pyrrolo [2,3-d] pyrimidine
CN116897156A (zh) *	2020-09-08	2023-10-17	高德美控股有限公司	新型jak抑制剂化合物、其合成方法及其用途
JP2023544495A (ja) *	2020-09-11	2023-10-24	ガルデルマホールディングエスエー	新規ｊａｋ阻害剤化合物、その合成方法、及びその使用
US20250082638A1 (en)	2021-02-02	2025-03-13	Pfizer Inc.	Dosing Regime For Treatment of Chronic Hand Eczema
WO2023014049A1 (fr) *	2021-08-02	2023-02-09	한국화학연구원	Nouveau dérivé de pyrrolopyrimidine, son procédé de préparation et composition pharmaceutique le comprenant en tant que principe actif pour la prévention ou le traitement d'une maladie hépatique métabolique
CN118255769A (zh) *	2022-12-28	2024-06-28	格格巫（珠海）生物科技有限公司	一种立体异构体的制备方法及中间体
ES2993658B2 (es)	2023-06-27	2025-07-02	Moehs Iberica Sl	(3-(metil(7h-pirrolo[2,3-d]pirimidin-4-il)amino)ciclobutilo)carbamato de bencilo o una sal del mismo, procedimiento para su preparacion y su uso en la sintesis de abrocitinib
WO2025008772A2 (fr)	2023-07-06	2025-01-09	Pfizer Ireland Pharmaceuticals	Procédé de fabrication amélioré et intermédiaires pour un composé pyrrolo[2,3-d]pyrimidine et leur utilisation
ES3040374A1 (es)	2024-04-30	2025-10-30	Moehs Iberica Sl	Cocristales de N-{cis-3-[metil(7H-pirrolo[2,3-d]pirimidin-4-il)amino]ciclobutil}propano-1-sulfonamida

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3037980A (en)	1955-08-18	1962-06-05	Burroughs Wellcome Co	Pyrrolopyrimidine vasodilators and method of making them
PL176526B1 (pl)	1992-12-17	1999-06-30	Pfizer	Pirolopirymidyny jako związki o działaniu antagonistów czynnika uwalniającego kortykotropinę
JPH06329674A (ja)	1993-05-20	1994-11-29	Teijin Ltd	４―置換シクロヘキシルアミノ―ピロロ［２，３―ｄ］ピリミジン
JPH06329675A (ja)	1993-05-20	1994-11-29	Teijin Ltd	４―置換アルキルアミノ―ピロロ［２，３―ｄ］ピリミジン誘導体
JPH08134068A (ja)	1994-11-02	1996-05-28	Teijin Ltd	４―置換アルキルアミノ―ピロロ［２，３―ｄ］ピリミジン誘導体
US6051578A (en)	1996-02-12	2000-04-18	Pfizer Inc.	Pyrazolopyrimidines for treatment of CNS disorders
US6686366B1 (en)	1998-06-02	2004-02-03	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A3 receptor and uses thereof
US6232320B1 (en)	1998-06-04	2001-05-15	Abbott Laboratories	Cell adhesion-inhibiting antiinflammatory compounds
HRP20000885B1 (hr)	1998-06-19	2007-03-31	Pfizer Products Inc.	PIROLO[2,3-d]PIRIMIDINSKI SPOJEVI
PA8474101A1 (es)	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
CZ27399A3 (cs)	1999-01-26	2000-08-16	Ústav Experimentální Botaniky Av Čr	Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
EP1040831A3 (fr)	1999-04-02	2003-05-02	Pfizer Products Inc.	Utilisation d'antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
CA2371271A1 (fr)	1999-04-30	2000-11-09	Neurogen Corporation	Derives 9h-pyrimido[4,5-b]indoles: ligands specifiques de crf1
US6664252B2 (en)	1999-12-02	2003-12-16	Osi Pharmaceuticals, Inc.	4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
JP4078074B2 (ja)	1999-12-10	2008-04-23	ファイザー・プロダクツ・インク	ピロロ［２，３−ｄ］ピリミジン化合物
US20030187261A1 (en)	2000-01-07	2003-10-02	Libor Havlicek	Purine derivatives, process for their preparation and use thereof
CA2412560C (fr)	2000-06-26	2008-12-30	Pfizer Products Inc.	Composes pyrrolo[2,3-d]pyrimidine en tant qu'agents immunosuppresseurs
US6680324B2 (en)	2000-12-01	2004-01-20	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en)	2000-12-01	2004-01-06	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A3 receptor and uses thereof
US7301023B2 (en)	2001-05-31	2007-11-27	Pfizer Inc.	Chiral salt resolution
JP2005529062A (ja)	2001-11-30	2005-09-29	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	アデノシンａ１及びａ３受容体に特異的な化合物とその使用
US20030139427A1 (en)	2002-08-23	2003-07-24	Osi Pharmaceuticals Inc.	Bicyclic pyrimidinyl derivatives and methods of use thereof
AU2003299901A1 (en)	2002-10-04	2004-05-04	Merck And Co., Inc.	Thrombin inhibitors
JP2006508976A (ja)	2002-11-21	2006-03-16	ファイザー・プロダクツ・インク	３−アミノ−ピペラジン誘導体及び製造法
AR054416A1 (es)	2004-12-22	2007-06-27	Incyte Corp	Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
RU2384583C2 (ru) *	2005-07-29	2010-03-20	Пфайзер Продактс Инк.	ПИРРОЛО[2,3-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ И СИНТЕЗ
JP2007091649A (ja)	2005-09-29	2007-04-12	Taisho Pharmaceut Co Ltd	ピリミジン誘導体及びその使用に関連する治療方法
GB0526246D0 (en) *	2005-12-22	2006-02-01	Novartis Ag	Organic compounds
EP2007373A4 (fr)	2006-03-29	2012-12-19	Foldrx Pharmaceuticals Inc	Inhibition de la toxicité de l'alpha-synucléine
WO2008089310A2 (fr)	2007-01-18	2008-07-24	Lexicon Pharmaceuticals, Inc.	Méthodes et compositions utilisées dans le traitement de troubles corporels
WO2008089307A2 (fr)	2007-01-18	2008-07-24	Lexicon Pharmaceuticals, Inc.	Méthodes et compositions utilisés dans le traitement de la douleur, de l'inflammation et du cancer
EA201070572A1 (ru)	2007-11-07	2010-12-30	Фолдркс Фармасьютикалз, Инк.	Модуляция транспорта белков
CA2703987A1 (fr)	2007-11-08	2009-05-14	Pfizer Inc.	Derives d'acide cyclobutylcarboxylique
US8946239B2 (en)	2008-07-10	2015-02-03	Duquesne University Of The Holy Spirit	Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
BRPI0917459B1 (pt) *	2008-08-20	2017-09-12	Zoetis Services Llc	N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide
WO2010032200A1 (fr)	2008-09-18	2010-03-25	Pfizer Limited	Composés amides utiles en thérapie
AU2010308028A1 (en) *	2009-10-15	2012-04-19	Pfizer Inc.	Pyrrolo[2,3-d] pyrimidine compounds
WO2011068881A1 (fr)	2009-12-01	2011-06-09	Abbott Laboratories	Composés tricycliques innovants
CA2782720A1 (fr) *	2009-12-18	2011-06-23	Pfizer Inc.	Composes pyrrolo[2,3-d]pyrimidines
TW201129565A (en)	2010-01-12	2011-09-01	Hoffmann La Roche	Tricyclic heterocyclic compounds, compositions and methods of use thereof
BR112012020989A2 (pt)	2010-02-24	2016-05-03	Pfizer	composições veterinárias
JP6081354B2 (ja)	2010-07-16	2017-02-15	アジオスファーマシューティカルズ，インコーポレイテッド	治療活性組成物およびそれらの使用方法
WO2012009649A1 (fr)	2010-07-16	2012-01-19	Anderson Gaweco	Inhibiteurs mif et leurs utilisations
US8580762B2 (en)	2010-12-03	2013-11-12	Epizyme, Inc.	Substituted purine and 7-deazapurine compounds
US8987307B2 (en)	2011-03-03	2015-03-24	Hoffmann-La Roche Inc.	3-amino-pyridines as GPBAR1 agonists
RU2013157374A (ru)	2011-06-07	2015-07-20	Сумитомо Дайниппон Фарма Ко., Лтд.	Производное индазола и пирролопиридина и его фармацевтическое применение
JP2013010719A (ja)	2011-06-30	2013-01-17	Dainippon Sumitomo Pharma Co Ltd	ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
EP2796460B1 (fr) *	2011-12-21	2018-07-04	Jiangsu Hengrui Medicine Co. Ltd.	Dérivé pyrrole de cycle hétéroaryle à six chaînons, procédé de préparation de celui-ci, et ses utilisations médicinales
US20140018361A1 (en)	2012-07-11	2014-01-16	Nimbus Iris, Inc.	Irak inhibitors and uses thereof
JP6022063B2 (ja)	2012-07-20	2016-11-09	ゾエティス・エルエルシー	ヤヌスキナーゼ（ｊａｋ）阻害剤の投与計画
JP2014133739A (ja)	2012-12-12	2014-07-24	Dainippon Sumitomo Pharma Co Ltd	インダゾール誘導体またはピロロピリジン誘導体からなる医薬
CN105008362B (zh)	2013-02-22	2017-06-06	辉瑞大药厂	作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3‑d]嘧啶衍生物
JP6585158B2 (ja)	2014-08-12	2019-10-02	ファイザー・インク	ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体

2014
- 2014-02-11 CN CN201480009783.8A patent/CN105008362B/zh active Active
- 2014-02-11 SI SI201430459T patent/SI2958921T1/sl unknown
- 2014-02-11 PL PL14705887T patent/PL2958921T3/pl unknown
- 2014-02-11 ES ES17191163T patent/ES2713052T3/es active Active
- 2014-02-11 MA MA38347A patent/MA38347A1/fr unknown
- 2014-02-11 AP AP2015008664A patent/AP2015008664A0/xx unknown
- 2014-02-11 RS RS20190097A patent/RS58245B1/sr unknown
- 2014-02-11 JP JP2015558572A patent/JP6145179B2/ja active Active
- 2014-02-11 MY MYPI2015702431A patent/MY177476A/en unknown
- 2014-02-11 CN CN201710440379.1A patent/CN107089985B/zh active Active
- 2014-02-11 LT LTEP17191163.9T patent/LT3290421T/lt unknown
- 2014-02-11 CA CA2900703A patent/CA2900703C/fr active Active
- 2014-02-11 TR TR2019/02525T patent/TR201902525T4/tr unknown
- 2014-02-11 PE PE2015001766A patent/PE20151764A1/es active IP Right Grant
- 2014-02-11 MX MX2015010928A patent/MX374338B/es active IP Right Grant
- 2014-02-11 LT LTEP14705887.9T patent/LT2958921T/lt unknown
- 2014-02-11 KR KR1020157022489A patent/KR101787858B1/ko active Active
- 2014-02-11 BR BR112015019634-9A patent/BR112015019634B1/pt active IP Right Grant
- 2014-02-11 DK DK14705887.9T patent/DK2958921T3/da active
- 2014-02-11 ME MEP-2019-6A patent/ME03301B/fr unknown
- 2014-02-11 CU CUP2015000078A patent/CU24275B1/xx unknown
- 2014-02-11 PT PT17191163T patent/PT3290421T/pt unknown
- 2014-02-11 DK DK17191163.9T patent/DK3290421T3/en active
- 2014-02-11 EA EA201591255A patent/EA027879B1/ru unknown
- 2014-02-11 RS RS20171095A patent/RS56503B1/sr unknown
- 2014-02-11 EP EP14705887.9A patent/EP2958921B1/fr active Active
- 2014-02-11 NZ NZ710411A patent/NZ710411A/en unknown
- 2014-02-11 ES ES14705887.9T patent/ES2647525T3/es active Active
- 2014-02-11 ME MEP-2017-246A patent/ME02904B/fr unknown
- 2014-02-11 GE GEAP201413916A patent/GEP201606600B/en unknown
- 2014-02-11 EP EP17191163.9A patent/EP3290421B1/fr active Active
- 2014-02-11 HR HRP20171599TT patent/HRP20171599T2/hr unknown
- 2014-02-11 SI SI201431068T patent/SI3290421T1/sl unknown
- 2014-02-11 SG SG11201505816UA patent/SG11201505816UA/en unknown
- 2014-02-11 HU HUE14705887A patent/HUE037192T2/hu unknown
- 2014-02-11 AU AU2014220357A patent/AU2014220357B2/en active Active
- 2014-02-11 PL PL17191163T patent/PL3290421T3/pl unknown
- 2014-02-11 MD MDA20150073A patent/MD4735C1/ro active IP Right Grant
- 2014-02-11 PT PT147058879T patent/PT2958921T/pt unknown
- 2014-02-11 WO PCT/IB2014/058889 patent/WO2014128591A1/fr not_active Ceased
- 2014-02-11 HU HUE17191163A patent/HUE041778T2/hu unknown
- 2014-02-19 TW TW103105469A patent/TWI507408B/zh active
- 2014-02-19 US US14/183,946 patent/US9035074B2/en active Active
- 2014-02-20 UY UY0001035337A patent/UY35337A/es not_active Application Discontinuation
- 2014-02-21 AR ARP140100561A patent/AR094857A1/es active IP Right Grant
- 2014-09-24 NO NO14789648A patent/NO3052752T3/no unknown
- 2014-11-02 UA UAA201507511A patent/UA111804C2/uk unknown
2015
- 2015-04-21 US US14/691,606 patent/US9545405B2/en active Active
- 2015-05-18 US US14/715,046 patent/US9549929B2/en active Active
- 2015-07-23 IL IL240132A patent/IL240132B/en active IP Right Grant
- 2015-07-29 ZA ZA2015/05454A patent/ZA201505454B/en unknown
- 2015-07-30 CR CR20150395A patent/CR20150395A/es unknown
- 2015-08-12 PH PH12015501779A patent/PH12015501779B1/en unknown
- 2015-08-17 CL CL2015002303A patent/CL2015002303A1/es unknown
- 2015-08-18 TN TN2015000355A patent/TN2015000355A1/fr unknown
- 2015-08-21 DO DO2015000206A patent/DOP2015000206A/es unknown
2017
- 2017-05-11 JP JP2017094676A patent/JP2017165762A/ja active Pending
- 2017-10-26 CY CY20171101116T patent/CY1119502T1/el unknown
2019
- 2019-01-23 HR HRP20190152TT patent/HRP20190152T1/hr unknown
- 2019-01-30 CY CY20191100127T patent/CY1121468T1/el unknown
2021
- 2021-12-22 NL NL301155C patent/NL301155I2/nl unknown
2022
- 2022-01-12 CY CY2022003C patent/CY2022003I2/el unknown
- 2022-01-17 HU HUS2200003C patent/HUS2200003I1/hu unknown
- 2022-01-26 LT LTPA2022502C patent/LTC2958921I2/lt unknown
- 2022-02-01 NO NO2022004C patent/NO2022004I1/no unknown
- 2022-02-10 FR FR22C1006C patent/FR22C1006I2/fr active Active
- 2022-05-13 LU LU00261C patent/LUC00261I2/fr unknown

Also Published As

Publication number	Publication date
US20140243312A1 (en)	2014-08-28
CY1121468T1 (el)	2020-05-29
KR20150109434A (ko)	2015-10-01
US9035074B2 (en)	2015-05-19
EA201591255A1 (ru)	2016-03-31
LT2958921T (lt)	2017-11-27
ES2713052T3 (es)	2019-05-17
MA38347A1 (fr)	2017-10-31
GEP201606600B (en)	2017-01-10
TR201902525T4 (tr)	2019-03-21
ME02904B (fr)	2018-04-20
MX2015010928A (es)	2015-10-29
ES2647525T3 (es)	2017-12-22
MD4735C1 (ro)	2021-07-31
EP2958921A1 (fr)	2015-12-30
CN105008362B (zh)	2017-06-06
RS56503B1 (sr)	2018-02-28
LT3290421T (lt)	2019-02-25
ME03301B (fr)	2019-07-20
RS58245B1 (sr)	2019-03-29
EA027879B1 (ru)	2017-09-29
BR112015019634A2 (pt)	2019-12-17
LTPA2022502I1 (fr)	2022-03-10
AP2015008664A0 (en)	2015-08-31
JP2017165762A (ja)	2017-09-21
UY35337A (es)	2014-09-30
MX374338B (es)	2025-03-06
JP6145179B2 (ja)	2017-06-07
SI2958921T1 (sl)	2017-12-29
AR094857A1 (es)	2015-09-02
CL2015002303A1 (es)	2015-12-18
CA2900703A1 (fr)	2014-08-28
EP2958921B1 (fr)	2017-09-20
PL3290421T3 (pl)	2019-05-31
CN105008362A (zh)	2015-10-28
CN107089985B (zh)	2019-06-07
EP3290421A1 (fr)	2018-03-07
CY2022003I1 (el)	2022-03-24
CY2022003I2 (el)	2022-03-24
DK2958921T3 (da)	2017-11-06
NZ710411A (en)	2017-11-24
KR101787858B1 (ko)	2017-10-18
CY1119502T1 (el)	2018-03-07
HUE041778T2 (hu)	2019-05-28
EP3290421B1 (fr)	2019-01-02
HUS2200003I1 (hu)	2022-02-28
PL2958921T3 (pl)	2018-01-31
NL301155I2 (nl)	2022-02-23
PT2958921T (pt)	2017-11-20
JP2016509049A (ja)	2016-03-24
MD4735B1 (ro)	2020-12-31
MD20150073A2 (ro)	2016-01-31
CA2900703C (fr)	2017-11-28
AU2014220357B2 (en)	2017-04-27
CN107089985A (zh)	2017-08-25
SI3290421T1 (sl)	2019-03-29
AU2014220357A1 (en)	2015-08-06
LTC2958921I2 (fr)	2024-03-25
NL301155I1 (fr)	2021-12-22
CU24275B1 (es)	2017-10-05
PH12015501779A1 (en)	2015-12-02
PH12015501779B1 (en)	2015-12-02
SG11201505816UA (en)	2015-09-29
PE20151764A1 (es)	2015-12-03
US20150225408A1 (en)	2015-08-13
US9549929B2 (en)	2017-01-24
US9545405B2 (en)	2017-01-17
FR22C1006I1 (fr)	2022-03-25
HUE037192T2 (hu)	2018-08-28
US20150246048A1 (en)	2015-09-03
HRP20190152T1 (hr)	2019-03-22
IL240132B (en)	2020-09-30
TN2015000355A1 (fr)	2017-01-03
TW201443055A (zh)	2014-11-16
DK3290421T3 (en)	2019-03-18
DOP2015000206A (es)	2016-02-15
TWI507408B (zh)	2015-11-11
NO2022004I1 (no)	2022-02-01
CU20150078A7 (es)	2016-01-29
HRP20171599T2 (hr)	2018-11-16
FR22C1006I2 (fr)	2023-01-27
ZA201505454B (en)	2016-07-27
CR20150395A (es)	2015-09-23
PT3290421T (pt)	2019-03-01
NO3052752T3 (fr)	2018-06-16
MY177476A (en)	2020-09-16
IL240132A0 (en)	2015-09-24
UA111804C2 (uk)	2016-06-10
WO2014128591A1 (fr)	2014-08-28
HRP20171599T1 (hr)	2017-12-01
HK1213881A1 (zh)	2016-07-15
BR112015019634B1 (pt)	2022-09-20

Publication	Publication Date	Title
LUC00261I2 (fr)	2025-04-25
AP2016009275A0 (fr)	2016-06-30
BR112016014396A2 (fr)	2017-08-08
BR112016010555A2 (fr)	2017-08-08
BR112016008376A2 (fr)	2017-08-01
BR112015007533A2 (fr)	2017-08-22
BR102016010778A2 (fr)	2017-08-08
BR112014018502A2 (fr)	2017-06-20
BR112014019326A2 (fr)	2017-06-20
BR112014018516A2 (fr)	2017-06-20
BR112014018480A2 (fr)	2017-06-20
BR112014020341A2 (fr)	2017-06-20
BR112014021878A2 (fr)	2017-06-20
BR112016013340A2 (fr)	2017-08-08
BR112016007704A2 (fr)	2017-08-01
BR112016005705A2 (fr)	2017-08-01
BR112014018468A2 (fr)	2017-06-20
BR112014017901A2 (fr)	2017-06-20
BR112016000627A2 (fr)	2017-07-25
BR112015015948A2 (fr)	2017-08-15
BR112014018578A2 (fr)	2017-06-20
BR112014018483A2 (fr)	2017-06-20
BR112016011906A2 (fr)	2017-08-08
BR112015015312A2 (fr)	2017-08-15
BR112014024039A2 (fr)	2017-06-20